社員発表論文・学会発表 Publication and Conference presentation

Kurosawa N, Wakata Y, Inobe T, Kitamura H, Yoshioka M, Matsuzawa S, Kishi Y, Isobe M. Novel method for the high-throughput production of phosphorylation site-specific monoclonal antibodies. Sci Rep. 6:25174. 2016

PMID：27125496

Inoue K, Seki T, Shoji T, Matsumi C, and Watanabe T. A novel method for visualizing protein-protein interactions in living cells; for evaluating plasma membrane penetration and activity of PPI modulators simultaneously. Drug Discovery Chemistry 2016（ポスター発表）

Seki T, Lee B, Shelly J, Ikeda S, Fujii Y, Ueno M, Kitamura S, Perera R. Long noncoding RNAs as molecular markers for prostate cancer detection in men. RNA2016 (2016 joint annual meeting of the RNA Society and the RNA Society of Japan)

Hirayama M, Shibata H, Imamura K, Sakaguchi T, Hori K. High-mannose specific lectin and its recombinants from a carrageenophyta Kappaphycus alvarezii represent a potent anti-HIV activity through high-affinity binding to the viral envelope glycoprotein gp120. Mar Biotechnol. 18(1) :144-60, 2016

PMID：26593063

Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M, Kuwana M. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PLoS ONE 11(4): e0154285, 2016

PMID：27115353

Hayakawa T, Teye K, Hachiya T, Uehara R, Hashiguchi M, Kawakami T, Li X, Tsuchisaka A, Ohara K, Sogame R, Koga H, Hamada T, Ohata C, Furumura M, Ishii N, Fukano H, Shimozato K, Hashimoto T. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins. Eur. J. Dermatol., in press. [Epub ahead of print], 2016

PMID：27087683

Fujimoto M, Murakami A, Kurei S, Okiyama N, Kawakami A, Mishima M, Sato S, Seishima M, Suda T, Mimori T, Takehara K, Kuwana M. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. J Dermatol Sci. pii: S0923-1811(16)30806-4. doi: 10.1016/j.jdermsci.2016.09.013. [Epub ahead of print], 2016

PMID：27693019

Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respiratory Medicine 121 91-99, 2016

published online：http://www.sciencedirect.com/science/article/pii/S0954611116302827

Shu E, Kanoh H, Murakami A, Seishima M. Potential inhibition of development of rapidly progressive interstitial lung disease by prompt and sufficient immunosuppressive treatment in patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. J Dermatol. doi: 10.1111/1346-8138.13659. [Epub ahead of print], 2016

PMID：27774665

Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi YO, Murakami A, Hasegawa M, Kuwana M, Fujimoto M, Takehara K. Anti-MDA5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. doi: 10.1111/bjd.14882. [Epub ahead of print], 2016

PMID：27452897